This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Shaheen Tomah, M.D.
Associate Director, Clinical Development at Altimmune
Speaker

Profile

Dr. Tomah is Assoc. Director of Clinical Development at Altimmune and a physician-scientist with clinical and translational research training in diabetes, and metabolism. He completed his postdoctoral training at the renowned Joslin Diabetes Center and Harvard Medical School before joining Altimmune in 2022. He has authored numerous papers in obesity, diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD), presented at national and international meetings, and served as an external grant reviewer for the National Institutes of Health (NIH)/NCATS. A previous session chair during the 82nd American Diabetes Association Scientific Sessions, his work has been featured on ADA's Diabetes Core Update Podcast. Dr. Tomah spearheaded efforts that culminated in a grant award of more than $500k in industry funding to support Joslin's first MASLD screening study in 2020.

Agenda Sessions

  • Harnessing the Power of Dual Incretin Agonists to Target Cardiometabolic Diseases

    11:45am